Ventyx Biosciences, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDVentyx Biosciences, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 98), indicating clear outperformance against the broad market. Earnings growth of 36% provides fundamental context to the price action. Investors should exercise caution due to high volatility (132% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $13.96 | +0.25% | ABOVE |
| 50 SMA | $12.95 | +8.14% | ABOVE |
| 100 SMA | $10.36 | +35.17% | ABOVE |
| 150 SMA | $7.83 | +78.90% | ABOVE |
| 200 SMA | $6.47 | +116.47% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is VTYX in an uptrend right now?
VTYX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, VTYX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is VTYX overbought or oversold?
VTYX's RSI (14) is 73. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is VTYX outperforming the market?
VTYX has a Relative Strength (RS) Rating of 98 out of 99. Yes, VTYX is a market leader, outperforming 98% of all stocks over the past 12 months.
Where is VTYX in its 52-week range?
VTYX is trading at $14.00, which is 56% of its 52-week high ($25.00) and 52% above its 52-week low ($1.95).
How volatile is VTYX?
VTYX has a Beta of 2.05 and 52-week volatility of 132%. It's more volatile than the S&P 500 - expect bigger swings.